Moderna seeks U.S., EU vaccine authorization

Video Credit: Reuters - Politics
Published on November 30, 2020 - Duration: 01:59s

Moderna seeks U.S., EU vaccine authorization

[NFA] Moderna will apply for U.S. and European emergency-use authorization for its COVID-19 vaccine on Monday after full results from a late-stage study showed it was 94.1% effective with no serious safety concerns, the company said.

Lisa Bernhard produced this report.


Moderna seeks U.S., EU vaccine authorization

In another major step forward in combatting the coronavirus, pharmaceutical company Moderna will apply for U.S. and European emergency authorization for its COVID-19 vaccine on Monday after the company said full results from a late-stage study showed it was 94.1% effective with no serious safety concerns.

Moderna also reported that its vaccine’s efficacy rate was consistent across age, race, ethnicity and gender demographics as well as having a 100% success rate in preventing severe cases of a disease that has killed nearly 1.5 million people worldwide.

After seeing the results, Moderna’s Chief Medical Officer told Reuters he became overwhelmed with emotion, saying "It was the first time I allowed myself to cry.

At this level of effectiveness, when you just do the math of what it means for the pandemic that's raging around us, it's just overwhelming." Moderna is the second company to seek emergency-use authorization after Pfizer, which reported that its vaccine, made in conjunction with BioNTech, had a 95% efficacy rate.

In an interview on CBS This Morning on Monday, Health and Human Services Secretary Alex Azar said it wouldn’t be long before those most vulnerable – like nursing home residents and front line health care workers – would be receiving the vaccines.

"We could be seeing both of these vaccines out and into people's arms before Christmas." Moderna's distribution is expected to be easier than Pfizer’s because while Moderna’s vaccine needs to be stored in a freezer, it does not require the ultra-cold temperature that Pfizer’s does.

In addition to filing its U.S. application, Moderna said it would seek conditional approval from the European Medicines Agency, which is already reviewing its data.

Moderna shares jumped to a record high on Monday – a rise of more than 600% this year.

You are here


💡 newsR Knowledge: Other News Mentions



Pfizer

Multinational pharmaceutical corporation
The first real-world analysis of the Pfizer coronavirus vaccine suggests it is matching its performance in clinical trials, but raises serious questions about..
12 hours ago • Sky News


Related news from verified sources

US biotech company Moderna on Monday announced that it plans to request an Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) and...
on November 30, 2020 • Mid-Day

Moderna is conducting a clinical trial of about 30,000 participants, with half of the participants receiving the vaccine and the other half receiving a placebo,...
on November 12, 2020 • IndiaTimes

Related videos from verified sources

Cincy Children's Hospital tests AstraZeneca's COVID-19 vaccine 02:12
Video credit: WCPO Cincinnati - Published 2 weeks ago 

COVID: Moderna Vaccine Arrives In California After FDA Authorization 02:42
Video credit: CBS 5 SF KPIX - Published on December 22, 2020 

EU Authorizes Pfizer/BioNTech's COVID-19 Vaccine 01:02
Video credit: Wibbitz Top Stories - Published on December 21, 2020 

You might like